NCT01791244View on ClinicalTrials.gov

A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Multiple SclerosisRelapsing-Remitting

Interventions

DRUG

Rebif®

Trial Locations (14)

Unknown

Please contact the Merck Communications Service for Recruiting locations, Darmstadt

Research site, Angered

Research site, Ängelholm

Research Site, Danderyd

Research Site, Eksjö

Research Site, Gävle

Research Site, Karlstad

Research Site, KS Huddinge

Research Site, Linköping

Research Site, Malmö/Lund

Research Site, Motala

Research Site, Örnsköldsvik

Research Site, Skövde

Research Site, Trollhättan

All Listed Sponsors

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01791244 - A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device | Biotech Hunter | Biotech Hunter